These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 29461857)

  • 1. Pricing of monoclonal antibody therapies: higher if used for cancer?
    Hernandez I; Bott SW; Patel AS; Wolf CG; Hospodar AR; Sampathkumar S; Shrank WH
    Am J Manag Care; 2018 Feb; 24(2):109-112. PubMed ID: 29461857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer Drug Prices in the United States: Efficacy, Innovation, Clinical Trial Evidence, and Epidemiology.
    Michaeli DT; Michaeli T
    Value Health; 2023 Nov; 26(11):1590-1600. PubMed ID: 37516196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoclonal Antibodies: A Review.
    Singh S; Kumar NK; Dwiwedi P; Charan J; Kaur R; Sidhu P; Chugh VK
    Curr Clin Pharmacol; 2018; 13(2):85-99. PubMed ID: 28799485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Applying a cost-based pricing model for innovative cancer treatments subject to indication expansion: A case study for pembrolizumab and daratumumab.
    Heine RJSD; Thielen FW; Mathijssen RHJ; van Leeuwen RWF; Franken MG; Uyl-de Groot CA
    PLoS One; 2024; 19(2):e0293264. PubMed ID: 38300937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trends in the Price per Median and Mean Life-Year Gained Among Newly Approved Cancer Therapies 1995 to 2017.
    Chen AJ; Hu X; Conti RM; Jena AB; Goldman DP
    Value Health; 2019 Dec; 22(12):1387-1395. PubMed ID: 31806195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Value and Price of Multi-indication Cancer Drugs in the USA, Germany, France, England, Canada, Australia, and Scotland.
    Michaeli DT; Mills M; Kanavos P
    Appl Health Econ Health Policy; 2022 Sep; 20(5):757-768. PubMed ID: 35821360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Examining Trends in Cost and Clinical Benefit of Novel Anticancer Drugs Over Time.
    Saluja R; Arciero VS; Cheng S; McDonald E; Wong WWL; Cheung MC; Chan KKW
    J Oncol Pract; 2018 May; 14(5):e280-e294. PubMed ID: 29601250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential cost savings by dose down-rounding of monoclonal antibodies in a community cancer center.
    Copur MS; Gnewuch C; Schriner M; Tharnish M; Gonen M; McDonald M; Kezeor J; Ramaekers RC; Gauchan D; Clark D; Greenwalt L; Mickey M; Norvell M
    J Oncol Pharm Pract; 2018 Mar; 24(2):116-120. PubMed ID: 29284380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient-Reported Outcomes Labeling for Products Approved by the Office of Hematology and Oncology Products of the US Food and Drug Administration (2010-2014).
    Gnanasakthy A; DeMuro C; Clark M; Haydysch E; Ma E; Bonthapally V
    J Clin Oncol; 2016 Jun; 34(16):1928-34. PubMed ID: 27069082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Price analysis of multiple sclerosis disease-modifying therapies marketed in the United States.
    Bin Sawad A; Seoane-Vazquez E; Rodriguez-Monguio R; Turkistani F
    Curr Med Res Opin; 2016 Nov; 32(11):1783-1788. PubMed ID: 27359262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fixed-dose combination and single active ingredient drugs: a comparative cost analysis.
    Hao J; Rodriguez-Monguio R; Seoane-Vazquez E
    Expert Rev Pharmacoecon Outcomes Res; 2016; 16(1):127-34. PubMed ID: 26174631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis.
    Iyengar S; Tay-Teo K; Vogler S; Beyer P; Wiktor S; de Joncheere K; Hill S
    PLoS Med; 2016 May; 13(5):e1002032. PubMed ID: 27243629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncology pharma costs to exceed $150 billion by 2020.
    Manag Care; 2016 Oct; 25(10):40. PubMed ID: 28121547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Price comparison of high-cost originator medicines in European countries.
    Vogler S; Zimmermann N; Babar ZU
    Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):221-230. PubMed ID: 27658050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Omalizumab: anti-IgE monoclonal antibody E25, E25, humanised anti-IgE MAb, IGE 025, monoclonal antibody E25, Olizumab, Xolair, rhuMAb-E25.
    BioDrugs; 2002; 16(5):380-6. PubMed ID: 12408744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer Drug Price and Novelty in Mechanism of Action.
    Miljkovic MD; Tuia J; Olivier T; Haslam A; Prasad V
    JAMA Netw Open; 2023 Dec; 6(12):e2347006. PubMed ID: 38079171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of generic reference pricing on medicine cost in Slovenia: a retrospective study.
    Marđetko N; Kos M
    Croat Med J; 2018 Apr; 59(2):79-89. PubMed ID: 29740992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Necitumumab in Metastatic Squamous Cell Lung Cancer: Establishing a Value-Based Cost.
    Goldstein DA; Chen Q; Ayer T; Howard DH; Lipscomb J; Ramalingam SS; Khuri FR; Flowers CR
    JAMA Oncol; 2015 Dec; 1(9):1293-300. PubMed ID: 26313558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer Drugs: An International Comparison of Postlicensing Price Inflation.
    Savage P; Mahmoud S; Patel Y; Kantarjian H
    J Oncol Pract; 2017 Jun; 13(6):e538-e542. PubMed ID: 28605615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail?
    Hartung DM; Bourdette DN; Ahmed SM; Whitham RH
    Neurology; 2015 May; 84(21):2185-92. PubMed ID: 25911108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.